Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. NERV
NERV logo

NERV News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

NERV News

Minerva Neurosciences to Host KOL Event on Schizophrenia Treatment

Jan 26 2026Newsfilter

Tuesday's Major Stock Market Highlights: Morning News Summary!

Oct 21 2025TipRanks

Minerva Neurosciences Soars 339% Following $200M Financing Deal

Oct 21 2025NASDAQ.COM

What’s Behind the 165% Surge in Minerva Neurosciences Stock (NERV) Today?

Oct 21 2025TipRanks

Minerva Neurosciences Gains Ground with Up to $200M Funding to Develop Schizophrenia Treatment

Oct 21 2025SeekingAlpha

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

May 13 2025Newsfilter

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

Feb 25 2025Newsfilter

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

Nov 05 2024Newsfilter

NERV Events

12/23 18:30
Dow and S&P Futures Dip Marginally, Nasdaq Flat
In the opening hour of the evening session, equity futures are down marginally, with Dow Industrials and S&P e-minis off by a decimal while Nasdaq 100 contract is trading flat.  In commodities, WTI Crude Oil is little changed after API inventory data saw its first build in multiple weeks, while precious metals have broken out to fresh record highs - Gold above $4,525 and Silver approaching $72 per ounce.Treasuries traded mixed with conflicting data in the form of much stronger than expected Q3 GDP and a much more recent cautionary story from December Conference Board Consumer Confidence report, which fell to its lowest level since the "tariff tantrum" in April - the yield on the 10-year Treasury ended around 4.17% after reaching 4.20% earlier.New record high close in the S&P 500 index was paced by Communication Services and Technology sectors, while Staples lagged once again.  Nvidiawas especially strong with a 3% advance, though the stock still trades off by over 10% from its highs in October.  Alphabetas well as Amazonalso notched respectable gains of about 1.5%.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Limoneiraup 0.9%ALSO HIGHER -Ramaco Resourcesup 6.7% after announcing $100M buybackUiPathup 3.7% after admission into S&P MidCap 400DOWN AFTER EARNINGS -Good Times Restaurantsdown 1.5%ALSO LOWER -Minerva Neurosciencesdown 3.9% after selling stock for holdersOrganogenesis Holdingsdown 3.4% after initiating rolling submission of BLA to FDA for ReNu
12/23 16:10
Minerva Files to Sell 94.6M Shares of Common Stock
Minerva files to sell 94.6M shares of common stock for holders
12/01 15:20
Jefferies Raises Minerva Price Target to $5, Maintains Hold Rating
Jefferies raised the firm's price target on Minerva to $5 from $3 and keeps a Hold rating on the shares. Oral roluperidone has the potential to benefit the negative symptoms of schizophrenia, an indication with no approved therapies, the analyst tells investors in a research note, adding that management has aligned with the FDA to initiate a confirmatory Phase III trial in 2026. The firm also said that, ultimately, it expects Minerva stock to climb on decreased time value to the Phase III dataset in 2028.

NERV Monitor News

No data

No data

NERV Earnings Analysis

No Data

No Data

People Also Watch